Summary of Purpose
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.Read More →
The following dates are available for this trial. Trial information last updated on 19 April 2018.
|22 Dec 2011||11 Sep 2013||31 Dec 2018||31 Dec 2019||1 Mar 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Conditions See All
- Bayer Clinical Trials Contact